Mark G Foletta insider trades
Open-market stock purchases and sales by Mark G Foletta, Director at DexCom Inc, from SEC Form 4 filings since Feb 2, 2010.
Recent trades
| Date | Stock | Trade | Value |
|---|---|---|---|
| Aug 3, 2026 | DXCM DexCom Inc | Sold | $171K |
| Jul 31, 2026 | DXCM DexCom Inc | Sold | $160K |
| Jun 15, 2026 | AMN AMN HealthCare Services Inc | Sold | $52.2K |
| Jun 15, 2026 | AMN AMN HealthCare Services Inc | Sold | $62.1K |
| Jun 15, 2026 | DXCM DexCom Inc | Sold | $282K |
| Jun 15, 2026 | DXCM DexCom Inc | Sold | $14.9K |
| May 28, 2026 | DXCM DexCom Inc | Bought (not open market) | — |
| May 8, 2026 | DXCM DexCom Inc | Bought (not open market) | — |
| May 1, 2026 | AMN AMN HealthCare Services Inc | Bought (not open market) | — |
| May 1, 2026 | AMN AMN HealthCare Services Inc | Bought (not open market) | — |
| Mar 11, 2026 | ENTA Enanta Pharmaceuticals Inc | Bought (not open market) | — |
Companies traded
- DXCM DexCom Inc: 91 sales, last Aug 3, 2026
- AMN AMN HealthCare Services Inc: 1 buy, 9 sales, last Jun 15, 2026
- ENTA Enanta Pharmaceuticals Inc: other filings, last Mar 11, 2026
- TOCA Tocagen Inc: 2 buys, last Oct 4, 2019
- RGLS Regulus Therapeutics Inc: 1 buy, last Dec 4, 2017
- AHS AMN HealthCare Services Inc: other filings, last Apr 20, 2016
- BIOC Biocept Inc: other filings, last Aug 31, 2015
- AMBI Ambit Biosciences Corp: other filings, last Nov 10, 2014
- "RGLS" Regulus Therapeutics Inc: other filings, last May 22, 2014
- AMLN Amylin Pharmaceuticals Inc: 2 sales, last Aug 8, 2012
- ANDS Anadys Pharmaceuticals Inc: other filings, last May 27, 2011